Ginkgolide-Based Hormonal Compositions for Cellular Stabilization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current hormonal and dietary compositions fail to effectively address alkyl- and acyl-like destabilizations of cells, leading to impaired cellular and organ function, particularly exacerbated by alcohol and nicotine use, resulting in conditions such as albuminuria, hematuria, and increased risk of diabetes and hypertension.
Innovation Solution
A novel composition combining prehormones, hormones, minerals, and Ginkgoloides, which inhibit the binding of alkyl groups mediated by AAGPC, thereby stabilizing cellular energy balance and hormone synthesis, and when combined with acetylcysteine, antagonizes hypersensitivity syndromes, promoting hormonal equilibration and cellular protection.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional hormonal and dietary compositions are used, then basic nutritional needs are met, but they fail to address alkyl- and acyl-like destabilizations of cells, leading to impaired cellular and organ function
Solution Approach 1:
The patent combines multiple active ingredients (Ginkgolides, acetylcysteine, minerals, vitamins, amino acids) into a composite dietary composition that addresses multiple cellular destabilization mechanisms simultaneously. This composite approach enables the formulation to tackle both conventional nutritional needs and specific alkyl-acyl destabilizations that single-ingredient compositions cannot address.
Solution Approach 2:
The invention introduces specific parameter changes by incorporating compounds that modify cellular response to alkyl and acyl groups. Ginkgolides specifically bind to and neutralize alkyl-acyl-GPC, while acetylcysteine modifies cellular thiol groups, changing the chemical parameters of cellular interaction with destabilizing agents.
2Use of energy by moving object
If alkyl lipids are present in the organism, then energy balance is influenced, but they cause unexpected early impairments including albuminuria, hematuria, and increased risk of diabetes and hypertension
Solution Approach 1:
The patent converts the harmful effect of alkyl-acyl-GPC into a beneficial one by using Ginkgolides to specifically bind these compounds. The bound alkyl-acyl-GPC-Ginkgolide complex is then excreted harmlessly, transforming the previously harmful alkyl lipids into a manageable and eliminable form that no longer causes cellular destabilization.
Solution Approach 2:
Ginkgolides act as intermediary substances that mediate between the harmful alkyl-acyl-GPC and the cellular systems. By binding to the destabilizing agents first, Ginkgolides prevent direct interaction between alkyl lipids and cellular membranes, organs, and tissues, thereby protecting against albuminuria, hematuria, and metabolic disturbances.
3Reliability
If hormones are used to treat cellular impairments, then some therapeutic effects are achieved, but hormones can aggravate alkyl-related impairments and cause hypersensitivity syndromes
Solution Approach 1:
The composition applies preliminary anti-action by incorporating Ginkgolides and acetylcysteine that preemptively neutralize alkyl-acyl-GPC and protect cellular thiol groups before hormones can interact with destabilized systems. This preliminary protection prevents the formation of hypersensitivity syndromes and hormone-aggravated impairments, allowing safe hormonal therapy.
Solution Approach 2:
The patent provides beforehand cushioning by including antioxidants and thiol-protecting agents that create a protective buffer against oxidative stress and cellular destabilization. This cushioning effect absorbs the harmful impact of alkyl lipids before they can trigger hypersensitivity responses to hormonal treatment.
4Quantity of substance
If free albumin is reduced due to alkyl lipid transport, then alkyl lipids can be carried, but protective free albumin becomes depleted leading to tissue damage
Solution Approach 1:
The patent extracts and removes alkyl-acyl-GPC from the system using Ginkgolides, preventing these compounds from binding to and depleting free albumin. By extracting the harmful alkyl agents, the formulation preserves free albumin levels and maintains its protective function while still allowing necessary albumin-mediated transport of beneficial substances.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The novel composition effectively treats alkyl- and acyl-like hypersensitivity syndromes, stabilizes cellular energy balance, and reduces the risk of diabetes and hypertension, while also addressing skin and connective tissue impairments, promoting overall health and well-being by equilibrating hormonal metabolism.
Implementation Method 1
Ginkgoloides inhibit here the binding of the alkyl-group mediating enrichment of cellular AAGPC by intermediate of LDL
Implementation Method 2
Ginkgoloides are combined here for the first time with acetylcysteine to antagonize the hypersensitivity syndromes
Implementation Method 3
The compositions are novel and fresh and inventive and comprising at least one prehormone, peptide-proteo-hormone, Ginkgoloide, mineral, trace element. Hormonal and/or dietary compositions are used for the first time for a hormonal, determinative equilibration.
Implementation Method 4
AAGPC is the mother compound of alkyl lipids and of the acyl-, choline groups for determination/impressing therewith the energy balance of all cells
Data Source
AI summary
The invention refers to novel compositions with at least one prehormone, hormone from group consisting of mevalonate derivatives or from the group consisting of peptides and/or proteohormones and at least one mineral, constituent by preference iodine, selen and at least one Ginkgoloide against alkyl-acyl-GPC (AAGPC), its derivatives (alkyllipids) and/or products (e.g. acetylacyl-CoA). These new hormonal compositions are manufactured with at least one Ginkgoloide and/or acetylcysteine for oral, dietary, oily or local, cosmetic administration. Novel cosmetic preparations without addition of ether/volatile oils contain Ginkgoloides with at least one sun screening agent against impairments of pigmentation. The novel compositions are manufactured with prehormones and constituents to protect against alkylacyl-like destabilization of cells by preference under the conditions of critical lifestyle, critical morning urine samples and/or hypersensitivity syndromes.